Moneycontrol PRO
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

Glenmark Pharma launches drug for treatment of Type 2 diabetes in adults

The launch of the drug is welcome news for diabetic patients with insulin resistance, which happens to be a common problem in India with every four out of ten diabetic patients showing insulin resistance in India.

October 06, 2022 / 10:34 AM IST
Representative Image.

Representative Image.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals on October 6 announced that it has become the first company in India to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) for the treatment of Type 2 diabetes in adults.

The drug is being marketed under the brand name LOBG, contains Lobeglitazone (0.5 millgrams) and is to be taken once daily under prescription to improve glycemic control in adult diabetic patients, the company said in a statement.

According to Glenmark, Indians have a high prevalence of what can be termed as 'insulin resistance', thus LOBG is a viable option for controlling Type 2 diabetes among insulin‐resistant diabetic patients. Data collected by the International Diabetes Federation suggests every four out of ten diabetic patients seem to have insulin resistance in India.

The Drug Controller General of India (DCGI) gave the pharma company approval to manufacture and market Lobeglitazone based on a randomized, double‐blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of this trial showed that patient on LOBG had a faster and improved glycemic control.

Also Read: India among top ten countries with highest Type 2 diabetes prevalence: Lancet study

Commenting on the launch of the drug Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals, said,

“As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40% of them seem to be insulin‐resistant. As a leading solutions provider in India for the treatment of diabetes, we are proud to introduce LOBG; an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.”

Also Read: COVID-19 linked with higher risk of type 1 diabetes in young people: Study 

Health information technology and clinical research company IQVIA found that in the sales data for the 12‐month period ending Aug. 2022, the market for oral anti‐diabetic drugs in India is estimated to be Rs 11,725 crore with an annual growth of 7% against the corresponding period last year.

Data from the International Diabetes Federation also suggests that, the prevalence of diabetes in India is expected to increase to 125 million by 2045.
Moneycontrol News